Alluvi, previously BI 4744, represents a significant advance in obesity care. This dual activator targeting both GLP-1 and GIP sites demonstrates remarkable effectiveness in patient trials, possibly exceeding existing https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/